You are here:

Forthcoming Submission: letermovir (Prevymis)

Indication: Prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant

Drug Details

Drug Name: letermovir (Prevymis)
Drug Manufacturer: MSD
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
SMC Meeting Date: Q2 2018
Advice Due: Q3 2018